This activity has been designed to meet the educational needs of medical, surgical and radiation oncologists and hematologists.
LEARNING OBJECTIVES :
Upon completion of this activity, participants should be able to:
- Evaluate the implications of emerging clinical trial data, including those presented at the 2008 ASCO annual meeting in breast, gastrointestinal, thoracic, genitourinary and hematologic cancer, and apply relevant information to current clinical practice.
- Incorporate new data from ASCO plenary and poster sessions, other major oncology conferences and peer-reviewed publications into management strategies in the neoadjuvant, adjuvant, locally advanced, metastatic and preventive settings across numerous tumor types.
- Assess the ongoing trials in breast, gastrointestinal, thoracic, genitourinary and select hematologic cancers and their potential long-term impact on approaches to patient care.
- Appraise the rationale for targeting EGFR, VEGF and other cellular pathways and the current and future roles of monoclonal antibodies and tyrosine kinase inhibitors in the management of common malignancies.
- Review the findings from recent clinical trials designed to test the efficacy and safety of various combination chemotherapeutic approaches in patients with advanced-stage disease.
- Utilize individualized risk factors, cytogenetics and demographics to tailor therapy for patients with hematologic malignancies.
CME EVALUATION :
An Evaluation Form will be given to each participant at the conclusion of this activity.
ACCREDITATION STATEMENT:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT:
Research To Practice designates this educational activity for a maximum of 5.9 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
DISCLOSURE POLICY:
As a provider accredited by the Accreditation Council for Continuing Medical Education, it is the policy of Research To Practice to require the disclosure of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Financial disclosures and disclosures of discussions of unlabeled/unapproved uses of drugs or devices will be provided in meeting course materials.
